Ajay Sheshadri

Ajay Sheshadri

Auto-generated profile, based on publicly available information

Ajay Sheshadri

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2014 in JAMA
Verified
Journal Article
Closed access
MCMario Castro
Mario Castro
TKTonya S. King
Tonya S. King
SKSusan J. Kunselman
Susan J. Kunselman
MCMichael D. Cabana
Michael D. Cabana
LDLoren Denlinger
Loren Denlinger
ESE. Rand Sutherland
E. Rand Sutherland
In asthma and other diseases, vitamin D insufficiency is associated with adverse outcomes. It is not known if supplementing inhaled corticosteroids with oral vitamin D3 improves outcomes in patients with asthma and vitamin D insufficiency. To evaluate if vitamin D supplementation would improve the clinical efficacy of inhaled corticosteroids in patients with symptomatic asthma and lower vitamin D levels. The VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma) randomized, double-blind, parallel, placebo-controlled trial studying adult patients with symptomatic asthma and a serum 25-hydroxyvitamin D level of less than 30 ng/mL was conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by January 2014. After a run-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized. Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n = 201) or placebo (n = 207) was added to inhaled ciclesonide (320 µg/d). If asthma control was achieved after 12 weeks, ciclesonide was tapered to 160 µg/d for 8 weeks, then to 80 µg/d for 8 weeks if asthma control was maintained. The primary outcome was time to first asthma treatment failure (a composite outcome of decline in lung function and increases in use of β-agonists, systemic corticosteroids, and health care). Treatment with vitamin D3 did not alter the rate of first treatment failure during 28 weeks (28% [95% CI, 21%-34%] with vitamin D3 vs 29% [95% CI, 23%-35%] with placebo; adjusted hazard ratio, 0.9 [95% CI, 0.6-1.3]). Of 14 prespecified secondary outcomes, 9 were analyzed, including asthma exacerbation; of those 9, the only statistically significant outcome was a small difference in the overall dose of ciclesonide required to maintain asthma control (111.3 µg/d [95% CI, 102.2-120.4 µg/d] in the vitamin D3 group vs 126.2 µg/d [95% CI, 117.2-135.3 µg/d] in the placebo group; difference of 14.9 µg/d [95% CI, 2.1-27.7 µg/d]). Vitamin D3 did not reduce the rate of first treatment failure or exacerbation in adults with persistent asthma and vitamin D insufficiency. These findings do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic asthma. clinicaltrials.gov Identifier: NCT01248065.

Verified
Journal Article
Open access
PDF file
Qasem Al-TashiQasem Al-Tashi
Qasem Al-Tashi
MSMaliazurina B Saad
Maliazurina B Saad
Amgad MuneerAmgad Muneer
Amgad Muneer
Rizwan QureshiRizwan Qureshi
Rizwan Qureshi
Seyedali MirjaliliSeyedali Mirjalili
Seyedali Mirjalili
Jia WuJia Wu
Jia Wu
The identification of biomarkers plays a crucial role in personalized medicine, both in the clinical and research settings. However, the contrast between predictive and prognostic biomarkers can be challenging due to the overlap between the two. A prognostic biomarker predicts the future outcome of cancer, regardless of treatment, and a predictive biomarker predicts the effectiveness of a therapeutic intervention. Misclassifying a prognostic biomarker as predictive (or vice versa) can have serious financial and personal consequences for patients. To address this issue, various statistical and machine learning approaches have been developed. The aim of this study is to present an in-depth analysis of recent advancements, trends, challenges, and future prospects in biomarker identification. A systematic search was conducted using PubMed to identify relevant studies published between 2017 and 2023. The selected studies were analyzed to better understand the concept of biomarker identification, evaluate machine learning methods, assess the level of research activity, and highlight the application of these methods in cancer research and treatment. Furthermore, existing obstacles and concerns are discussed to identify prospective research areas. We believe that this review will serve as a valuable resource for researchers, providing insights into the methods and approaches used in biomarker discovery and identifying future research opportunities.

21 November 2017 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
TFTakeo Fujii
Takeo Fujii
RCRivka R. Colen
Rivka R. Colen
MBMehmet Asim Bilen
Mehmet Asim Bilen
KHKenneth R. Hess
Kenneth R. Hess
JHJoud Hajjar
Joud Hajjar
ANAung Naing
Aung Naing

1 January 2015 in Radiology
Verified
Journal Article
Closed access
RTRobert P. Thomen
Robert P. Thomen
ASAjay Sheshadri
Ajay Sheshadri
JQJames D. Quirk
James D. Quirk
JKJim Kozlowski
Jim Kozlowski
HEHenry D. Ellison
Henry D. Ellison
JWJason C. Woods
Jason C. Woods
We quantified regional lung ventilation in healthy volunteers and patients with severe asthma (both before and after thermoplasty) at the level of individual bronchopulmonary segments by using a combination of 3He MR imaging and CT. PurposeTo quantify regional lung ventilation in healthy volunteers and patients with severe asthma (both before and after thermoplasty) by using a combination of helium 3 (3He) magnetic resonance (MR) imaging and computed tomography (CT), with the intention of developing more effective image-guided treatments for obstructive lung diseases.Materials and MethodsWith approval of the local institutional review board, informed consent, and an Investigational New Drug Exemption, six healthy volunteers and 10 patients with severe asthma were imaged in compliance with HIPAA regulations by using both multidetector CT and 3He MR imaging. Individual bronchopulmonary segments were labeled voxel by voxel from the CT images and then registered to the 3He MR images by using custom software. The 3He signal intensity was then analyzed by evaluating the volume-weighted fraction of total-lung signal intensity present in each segment (segmental ventilation percentage [SVPsegmental ventilation percentage]) and by identifying ...

11 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSheeba Jenifer Sujit
Sheeba Jenifer Sujit
MAMuhammad Aminu
Muhammad Aminu
TKTatiana V. Karpinets
Tatiana V. Karpinets
Pingjun ChenPingjun Chen
Pingjun Chen
MSMaliazurina B. Saad
Maliazurina B. Saad
Jia WuJia Wu
Jia Wu
While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplored. In our multi-institutional study of 394 NSCLC patients, we utilize pre-treatment computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to establish a habitat imaging framework for assessing regional heterogeneity within individual tumors. This framework identifies three PET/CT subtypes, which maintain prognostic value after adjusting for clinicopathologic risk factors including tumor volume. Additionally, these subtypes complement ctDNA in predicting disease recurrence. Radiogenomics analysis unveil the molecular underpinnings of these imaging subtypes, highlighting downregulation in interferon alpha and gamma pathways in the high-risk subtype. In summary, our study demonstrates that these habitat imaging subtypes effectively stratify NSCLC patients based on their risk levels for disease recurrence after initial curative surgery or radiotherapy, providing valuable insights for personalized treatment approaches.

27 October 2017 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
RCRivka R. Colen
Rivka R. Colen
TFTakeo Fujii
Takeo Fujii
MBMehmet Asim Bilen
Mehmet Asim Bilen
AKAikaterini Kotrotsou
Aikaterini Kotrotsou
SASrishti Abrol
Srishti Abrol
ANAung Naing
Aung Naing